Skip to main content
ATOSSA THERAPEUTICS, INC. logo

ATOSSA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ATOS ISIN · US04962H5063 US Manufacturing
Open in API
Filings indexed 622 across all filing types
Latest filing 2017-12-22 Capital/Financing Update
Country US United States of America
Listing US ATOS

About ATOSSA THERAPEUTICS, INC.

https://atossatherapeutics.com/

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative medicines for areas of significant unmet medical need, with a primary focus on oncology. The company is dedicated to addressing the full continuum of breast cancer care. Its lead program is centered on (Z)-endoxifen, a proprietary and potent selective estrogen receptor modulator (SERM). Atossa is advancing (Z)-endoxifen through clinical development for multiple breast cancer indications, including metastatic disease, aiming to provide a therapeutic with a potentially improved efficacy and tolerability profile.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the company's entry into a material definitive agreement related to a securities offering, including a placement agent agreement, securities purchase agreement, and issuance of warrants. It details the terms of the offering and private placement, including share amounts, prices, and warrant terms. There are no financial statements or comprehensive financial data presented, only disclosures about financing transactions. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is about 5932 characters, sufficient to contain substantive information about the financing event rather than just an announcement of a report. Therefore, the correct classification is CAP with high confidence.
2017-12-22 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement and base prospectus related to a public offering of common stock and warrants by Atossa Genetics Inc. It includes detailed terms of the offering, risk factors, use of proceeds, dividend policy, plan of distribution, and legal matters. The document is filed pursuant to Rule 424(b)(5), which is a prospectus supplement filing under the Securities Act. The content focuses on capital raising activities, including share issuance and warrant offerings, and does not contain financial statements or earnings data. Therefore, this document is best classified as a Capital/Financing Update (CAP).
2017-12-21 English
OWNERSHIP DOCUMENT
Director's Dealing
2017-11-16 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions that the company issued a press release announcing third quarter 2017 financial results and a company update, and that the press release is attached as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but refers to the press release for the results. The length of the document is 3134 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, if a document is short and announces or attaches a report (like a press release of earnings), it should be classified as a Regulatory Filing (RNS) rather than an Earnings Release (ER) or Interim Report (IR). Therefore, the appropriate classification is Regulatory Filings (RNS).
2017-11-14 English
10-Q
Interim / Quarterly Report 9M 2017
2017-11-13 English
Major Shareholding Notification 2017
Major Shareholding Notification
2017-11-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.